2011 Volume 63 Issue 4 Pages 477-482
We retrospectively reviewed 32 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIc ovarian cancer, who were primarily treated in our hospital between 2002 and 2008. We used the patients' charts and analyzed the details of their treatment. 5-year overall and disease-free survival rates were 51.2% and 47.3%, respectively. These rates were higher than those of the FIGO report in 2006. The recurrence rate of 7 cases who underwent optimal debulking surgery either primarily or secondarily was significantly lower than that of the 23 cases who did not (p=0.0042). In the primary suboptimal surgery group, the recurrence rate of 18 cases who underwent optimal debulking surgery was significantly lower than that of the 5 cases who did not undergo surgery because they achieved a clinical complete response (CR) with chemotherapy (p=0.0361). In the recurrence group, the overall survival rate of 10 cases treated with more than 5 cycles of salvage chemotherapy was significantly higher than that of the 3 cases who underwent less than 6 cycles of the same (p=0.0024). These results show that the combination of optimal debulking surgery, performed either primarily or secondarily, and continuing chemotherapy are important for prolonged survival of patients with recurrent stage IIIc ovarian cancer. [Adv Obstet Gynecol, 63(4) : 477-482, 2011(H23.11)]
